Compare Dropbox Inc (DBX) vs Heron Therapeutics Inc (HRTX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Dropbox Inc vs Heron Therapeutics Inc — how do they compare? Dropbox Inc trades at $33.64 (market cap $7.52B), while Heron Therapeutics Inc trades at $0.32 (market cap $63.41M). The key difference: Dropbox Inc is far larger — about 118.6× Heron Therapeutics Inc's market cap, and Dropbox Inc is trading nearer its 52-week high, Heron Therapeutics Inc nearer its low. Which is the better fit depends on your goals.
| DBX | HRTX | |
|---|---|---|
Market Cap | $7.52B | $63.41M |
Sector | Technology | Health |
52-Week High | $35.00 | $1.49 |
52-Week Low | $22.06 | $0.32 |
Enterprise Value | $10.38B | $161.31M |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Dropbox (DBX) trades at $34.81, up 0.78% today, with a bullish technical signal and consistent earnings beats. The company reported Q2 2026 EPS of $0.75, exceeding estimates, and raised its full-year outlook. Revenue remains stable at $2.5B, with strong gross margins of 79.72%. However, negative shareholder equity and high debt levels pose financial risks.
The outlook is mixed: strong profitability and AI-driven growth support upside, but elevated leverage and competitive pressures warrant caution. Analyst sentiment is divided, with 37.5% recommending Buy. Key risks include execution challenges and market volatility. The stock's trajectory hinges on sustaining core business momentum amid macroeconomic headwinds.
Heron Therapeutics (HRTX) trades at $0.49, down 1.64% today, with a bearish technical signal from moving averages. The company reported Q2 2026 revenue of $37.7M but missed earnings expectations with a $0.03 loss per share. Despite negative net income margins, HRTX maintains strong analyst support with 94.7% buy ratings. Recent news highlights patent litigation developments and quarterly earnings underperformance.
HRTX faces significant fundamental challenges with persistent losses and declining revenue projections, though analyst consensus remains overwhelmingly bullish. Investment opportunity exists if the company can achieve profitability and meet growth targets, but risks include ongoing operational losses, competitive pressures, and execution challenges in the biotechnology sector.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Dropbox Inc
Dropbox is a leading provider of cloud-storage and content collaboration tools with an emphasis on individuals and SMB. The company was founded in 2007 and was a pioneer in cloud storage and cross-platform file syncing. Utilizing inorganic and organic means, the firm has been working on diversifying its product mix and pivoting away from the cloud-storage space.
Read more on DBX →About Heron Therapeutics Inc
Heron Therapeutics is a commercial-stage biotechnology company focused on improving patient care. It develops best-in-class medicines for pain management and cancer care to address unmet medical needs.
Read more on HRTX →
